PE20081569A1 - Metodo para el tratamiento de sindrome del intestino irritable predominante-diarrea - Google Patents

Metodo para el tratamiento de sindrome del intestino irritable predominante-diarrea

Info

Publication number
PE20081569A1
PE20081569A1 PE2007000533A PE2007000533A PE20081569A1 PE 20081569 A1 PE20081569 A1 PE 20081569A1 PE 2007000533 A PE2007000533 A PE 2007000533A PE 2007000533 A PE2007000533 A PE 2007000533A PE 20081569 A1 PE20081569 A1 PE 20081569A1
Authority
PE
Peru
Prior art keywords
diarrhea
inhibitor
bowel syndrome
irritable bowel
predominant irritable
Prior art date
Application number
PE2007000533A
Other languages
English (en)
Original Assignee
Trine Pharmaceuticals Inc
Napo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38648619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081569(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trine Pharmaceuticals Inc, Napo Pharmaceuticals Inc filed Critical Trine Pharmaceuticals Inc
Publication of PE20081569A1 publication Critical patent/PE20081569A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN METODO PARA TRATAR EL SINDROME DEL INTESTINO IRRITABLE PREDOMINANTE-DIARREA, QUE COMPRENDE EN ADMINISTRAR UN INHIBIDOR DE TRANSPORTE DE ION CLORURO EN UNA CANTIDAD SUFICIENTE PARA TRATAR EL DOLOR Y EL MALESTAR ABDOMINAL ASOCIADO CON d-IBS; SIENDO SELECCIONADO COMO INHIBIDOR UN EXTRACTO DE CROTON SPP. O CALOPHYLLUM SPP.; UNA COMPOSICION POLIMERICA DE PROANTOCIANINA SIENDO PREFERIDO LA ADMINISTRACION CROFELEMER ENTRE 50 MG A 750 MG POR DIA; O UN INHIBIDOR DE LA FUNCION CFTR TAL COMO 2-TIOXO-4-TIAZOLIDINONA Y 3-[(3-TRIFLUOROMETIL)FENIL]-5-[(3-CARBOXIFENIL)METILEN]-2-TIOXO-4-TIAZOLIDINONA, TOLBUTAMINA, GLIBENCLAMIDA Y FLUORESCEINA O DERIVADOS O ANALOGOS DE LOS MISMOS, VERAPAMIL, NIFEDIPINA, HIDRAZIDAS, LOPERAMIDA, ENTRE OTROS. ADEMAS COMPRENDE LA ADMINISTRACION DE UN AGENTE ANALGESICO O ANTIINFLAMATORIO
PE2007000533A 2006-05-01 2007-05-02 Metodo para el tratamiento de sindrome del intestino irritable predominante-diarrea PE20081569A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79707406P 2006-05-01 2006-05-01
US11/510,152 US20070254050A1 (en) 2006-05-01 2006-08-24 Method for treatment of diarrhea-predominant irritable bowel syndrome

Publications (1)

Publication Number Publication Date
PE20081569A1 true PE20081569A1 (es) 2009-01-14

Family

ID=38648619

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000533A PE20081569A1 (es) 2006-05-01 2007-05-02 Metodo para el tratamiento de sindrome del intestino irritable predominante-diarrea

Country Status (18)

Country Link
US (3) US20070254050A1 (es)
EP (1) EP2034844B1 (es)
JP (2) JP5384329B2 (es)
KR (2) KR101537361B1 (es)
AR (1) AR060829A1 (es)
AU (1) AU2007248172B2 (es)
CA (1) CA2650294C (es)
DK (1) DK2034844T3 (es)
ES (1) ES2628290T3 (es)
MX (1) MX2008013871A (es)
NZ (2) NZ609344A (es)
PE (1) PE20081569A1 (es)
PL (1) PL2034844T3 (es)
PT (1) PT2034844T (es)
SG (1) SG174025A1 (es)
TR (1) TR201708043T4 (es)
TW (2) TWI574694B (es)
WO (1) WO2007130882A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
PL2241318T3 (pl) 2006-05-01 2013-05-31 Napo Pharmaceuticals Inc Sposób leczenia zespołu jelita drażliwego z dominującymi zaparciami
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
DK2529626T3 (en) * 2006-05-01 2018-01-22 Napo Pharmaceuticals Inc Compositions and Methods for Treating or Preventing Colon Cancer
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US20110263478A1 (en) * 2008-09-16 2011-10-27 Simard J Marc Sur1 inhibitors for therapy
JP4565219B2 (ja) * 2008-12-26 2010-10-20 アサヒビール株式会社 ポリフェノール含有顆粒またはポリフェノール含有チュアブル錠剤およびその製造方法
WO2011044167A1 (en) * 2009-10-06 2011-04-14 University Of California, San Francisco Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
SG181810A1 (en) * 2009-12-17 2012-07-30 Univ Singapore Method of preparing derivatives/oligomers of epicatechin and applications thereof
PE20140036A1 (es) * 2010-10-31 2014-01-31 Napo Pharmaceuticals Inc Metodos y composiciones para tratar diarrea asociada con vih
CA2832059C (en) * 2011-04-01 2020-07-14 Ocean Spray Cranberries, Inc. Inflammation and immunity treatments
US20140057993A1 (en) * 2011-04-27 2014-02-27 Northshore University Healthsystem Prophylaxis and Treatment of Enteropathogenic Bacterial Infection
CN108685929A (zh) * 2012-04-23 2018-10-23 苏坎波公司 用于治疗具有腹泻的肠易激综合征的方法
JP6121556B2 (ja) * 2012-11-21 2017-04-26 ケイビーエス リサーチ、 エルエルシー ハーブサプリメントおよびその使用の方法
US9717726B2 (en) * 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
KR101579688B1 (ko) 2014-07-08 2015-12-24 재단법인 전남생물산업진흥원 좁쌀풀 추출물을 유효성분으로 함유하는 과민성 대장증후군에 의한 내장 통증 억제예방 또는 치료용 약학 조성물
CN104873485B (zh) * 2015-05-08 2019-02-19 中国药科大学 槲皮素治疗与胃肠道应激失调相关疾病的用途
CN107125440A (zh) * 2016-02-29 2017-09-05 湖南晶天科技实业有限公司 一种饲料添加剂肠溶包衣单宁酸及其制备方法以及一种饲料
IT201600122310A1 (it) * 2016-12-01 2018-06-01 Sofar Spa Composizione per uso nella terapia di alterazioni dell'intestino
WO2018119464A1 (en) 2016-12-23 2018-06-28 Maregade Rx, LLC Low dose product and method for treating diarrhea
WO2018163195A1 (en) * 2017-03-06 2018-09-13 Athena Drug Delivery Solutions Pvt Ltd. A pharmaceutical composition comprising racecadotril and process for preparing the same
JOP20190276A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
JOP20190275A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي
CN114007623A (zh) * 2019-06-12 2022-02-01 加利福尼亚大学董事会 治疗胆汁酸性腹泻的方法
CN113975412B (zh) * 2021-12-30 2022-04-05 北京赛尔富森生物科技有限公司 一种评价轮状病毒疫苗有效性的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE446940B (sv) 1983-02-16 1986-10-20 Carl Axel Virdalm Medel for bekempande av sjukdomstillstand i matsmeltningsapparaten innehallande skal eller ytterdelar av ber eller frukter
US4698360B1 (en) 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
ATE36448T1 (de) 1985-08-30 1988-09-15 Nestle Sa Diaetetisches produkt mit blutreinigender und antidiarrhoel-wirksamkeit und verfahren zu seiner zubereitung.
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
SI9011933A (sl) 1990-10-15 1998-06-30 TANIN SEVNICA Kemična industrija p.o. Kostanjev taninski ekstrakt, postopek za njegovo pridobivanje in njegova uporaba
US5234922A (en) 1992-09-28 1993-08-10 University Of Iowa Research Foundation Use of sulfonylureas and other potassium channel regulators to treat secretory diarrhea
FI962667A (fi) 1996-06-27 1997-12-28 Scanwoven Ab Oy Kuitutuote, menetelmä ja laitteisto kuitutuotteen valmistamiseksi
DK0935417T3 (da) 1996-10-16 2009-08-10 Napo Pharmaceuticals Inc Enteroformuleringer af proanthocyanidin-polymer-sammensætninger mod diarré
AU6967198A (en) 1997-04-10 1998-10-30 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
US20040063695A1 (en) 2002-09-30 2004-04-01 Alan Verkman Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US7208183B2 (en) * 2002-10-05 2007-04-24 Bobrowski Paul J Methods and preparations of the latex from the croton species
US7303772B2 (en) * 2005-11-10 2007-12-04 Olalde Rangel Jose Angel Synergistic phytoceutical compositions
DK2529626T3 (en) 2006-05-01 2018-01-22 Napo Pharmaceuticals Inc Compositions and Methods for Treating or Preventing Colon Cancer
PL2241318T3 (pl) 2006-05-01 2013-05-31 Napo Pharmaceuticals Inc Sposób leczenia zespołu jelita drażliwego z dominującymi zaparciami
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
WO2011044167A1 (en) 2009-10-06 2011-04-14 University Of California, San Francisco Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
PE20140036A1 (es) 2010-10-31 2014-01-31 Napo Pharmaceuticals Inc Metodos y composiciones para tratar diarrea asociada con vih
JP2016505561A (ja) 2012-12-07 2016-02-25 サリックス ファーマスーティカルズ，リミテッド Ｈｉｖ関連下痢を治療する方法および組成物

Also Published As

Publication number Publication date
AU2007248172A1 (en) 2007-11-15
MX2008013871A (es) 2009-01-07
WO2007130882A2 (en) 2007-11-15
KR20090009291A (ko) 2009-01-22
JP5384329B2 (ja) 2014-01-08
NZ609344A (en) 2014-08-29
US20150050338A1 (en) 2015-02-19
EP2034844A2 (en) 2009-03-18
AU2007248172B2 (en) 2013-03-21
JP2014012695A (ja) 2014-01-23
TWI481410B (zh) 2015-04-21
WO2007130882A3 (en) 2008-02-07
US8846113B2 (en) 2014-09-30
EP2034844B1 (en) 2017-03-22
PL2034844T3 (pl) 2017-09-29
TWI574694B (zh) 2017-03-21
US9980938B2 (en) 2018-05-29
TW200810772A (en) 2008-03-01
US20070254050A1 (en) 2007-11-01
NZ595749A (en) 2013-11-29
JP5820440B2 (ja) 2015-11-24
US20120189720A1 (en) 2012-07-26
ES2628290T3 (es) 2017-08-02
CA2650294A1 (en) 2007-11-15
EP2034844A4 (en) 2010-11-17
KR20130063552A (ko) 2013-06-14
TW201434475A (zh) 2014-09-16
CA2650294C (en) 2019-01-22
AR060829A1 (es) 2008-07-16
JP2009535417A (ja) 2009-10-01
PT2034844T (pt) 2017-06-26
SG174025A1 (en) 2011-09-29
KR101537361B1 (ko) 2015-07-17
DK2034844T3 (en) 2017-06-06
TR201708043T4 (tr) 2018-11-21
KR101487919B1 (ko) 2015-02-03

Similar Documents

Publication Publication Date Title
PE20081569A1 (es) Metodo para el tratamiento de sindrome del intestino irritable predominante-diarrea
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
AR043987A1 (es) Composiciones farmaceuticas para administracion oral de agonistas del receptor de fosfato de esfingosina-1
PE20060594A1 (es) Composicion farmaceutica que contiene un agonista de ppar
HK1073427A1 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
CL2008002224A1 (es) Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer.
ATE548034T1 (de) Pharmazeutische zusammensetzungen mit droxidopa
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
CL2008003901A1 (es) Uso de un inhibidor de hedgehog para extender la sobrevida libre de recidiva en un paciente con cancer, que se encuentra en quimioterapia o ha sido tratado previamente con quimioterapia.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
WO2009020561A3 (en) Compositions and methods of use thereof, for the treatment of oral pain, comprising cloves or extract thereof in combination with a steroid
PE20071231A1 (es) Formulaciones farmaceuticas de pleconaril
MX2009011900A (es) Curacion de herida diabetica.
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
MX2009003912A (es) Metodos y composiciones usando compuestos inmunomoduladores para el tratamiento y manejo de enfermedades bacterianas por espiroquetas y otras bacterias intracelulares obligadas.
SV2006001916A (es) Formulaciones farmaceuticas transdermales
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
AR066666A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
PE20090524A1 (es) Composicion farmaceutica que comprende la combinacion de una triazolobenzodiazepina y un agente inhibidor selectivo de la recaptura de serotonina
PA8651401A1 (es) Formas de dosificacion oral solidas que contienen una dosis baja de estradiol
BRPI0519006A2 (pt) uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
AR046665A1 (es) Formulaciones orales de desoxipeganina y sus usos
AR037543A1 (es) Metodo para la terapia del cancer y composicion farmaceutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal